Dual ligand immunoliposomes for drug delivery to the brain

Targeted Nanoparticles for the Treatment of Alzheimer's Disease

“…For both factors the presence of suitable (and compatible) functional groups should be evaluated [160,163]. All the mentioned aspects are better highlighted in the reported works from the literature and some have been also explored in systems applied to AD treatment [164,165].…”

“…There is a relatively broad variety of fragments which have been used on the surface of nanocarriers to target Aβ peptides: curcumin [170][171][172][173], lipidic fragments (e.g. cardiolipin, and phosphatidic acid) [164,[174][175][176][177][178][179], antibodies [165,180,181], peptides [122,159,[182][183][184][185], and apolipoprotein [186]. Although some groups have focused their work on the development of targeted nanotools with potential for drug delivery or diagnosis [164,165,187,188], some other examples have already gone beyond and reported not only the targeting but also the delivery of therapeutics aiming at disaggregating Aβ plaques and oligomers [178,182,186,189].…”

Targeted nano-carriers to combat neurodegeneration

“…The OX26 monoclonal antibody has also been used to target the transferrin receptor on the BBB in vitro [123]. Other targeting strategies incorporated targeting ligands for both the transferrin receptor (for BBB targeting) as well as for aggregated protein deposits (for neuronal targeting) [68,[124][125][126][127].…”

“…Several targeting strategies have therefore used ligands to target these deposits. For example, a study incorporated an anti-Aβ peptide antibody along with an antitransferrin receptor monoclonal antibody, on a polyethylene glycol-modified liposomal platform to improve delivery [124]. There was an interplay where the conjugation method for each antibody affected cellular uptake [124].…”

“…For example, a study incorporated an anti-Aβ peptide antibody along with an antitransferrin receptor monoclonal antibody, on a polyethylene glycol-modified liposomal platform to improve delivery [124]. There was an interplay where the conjugation method for each antibody affected cellular uptake [124]. The same group later tested improvements in efficacy of a drug to treat Aβ aggregation in an AD model, again using dual functionalization of both anti-transferrin and anti-Aβ antibodies, but this time with PLGA NPs [78].…”